Recombinant RSV (Felvizumab Biosimilar) antibody
-
- Target See all RSV (Felvizumab Biosimilar) products
- RSV (Felvizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Respiratory Syncytial Virus (RSV)
-
Host
- Rabbit
-
Clonality
- Monoclonal
-
Conjugate
- This RSV (Felvizumab Biosimilar) antibody is un-conjugated
- Application
- ELISA, Functional Studies (Func)
- Specificity
- This antibody is specific for the conserved fusion (F) protein of RSV.
- Characteristics
-
OriginalSpeciesName: Human
OriginalFormat: IgG1
- Purification
- Purified antibody.
- Purity
- > 98 % as determined by SDS-PAGE
- Endotoxin Level
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
- Immunogen
- This antibody was prepared by the humanization of an F protein-specific murine MAb, RSV19. More specifically, molecular techniques were used to insert the complementarity determining regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework.
- Clone
- RSHZ19
- Isotype
- IgG kappa
-
-
- Application Notes
- Though shown to be safe and well-tolerated (Everitt, 1996) and protective against RSV infection in BALB/c mice and cotton rats (Wyde, 1995), this antibody did not demonstrate efficacy in a Phase 3 study (Reichert, 2008). In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999).
- Comment
-
This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
- Restrictions
- For Research Use only
-
- Buffer
- PBS with 0.02 % Proclin 300.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- Target
- RSV (Felvizumab Biosimilar)
- Abstract
- RSV (Felvizumab Biosimilar) Products
- Target Type
- Biosimilar
- Background
- SB 209763, respiratory syncytial virus
-